Skip to main content

Advertisement

SpringerLink
Log in

Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Therapies for osteoporosis must be taken for at least 1 year to be effective. The purpose of this study was to determine the difference in adherence to etidronate, alendronate and hormone replacement therapy in a group of patients seen at our tertiary care centres. The Canadian Database of Osteoporosis and Osteopenia (CANDOO), a prospective observational database designed to capture clinical data, was searched for patients who started therapy following entry into CANDOO. There were 1196 initiating etidronate, 477 alendronate and 294 hormone replacement therapy women and men aged (mean, SD) 65.8 (8.7) years in the study. A Cox proportional hazards regression model was used to assess differences between treatment groups in the time to discontinuation of therapy. Several potential covariates such as anthropometry, medications, illnesses, fractures and lifestyle factors were entered into the model. A forward selection technique was used to generate the final model. Hazard ratios and 95% confidence intervals (CI) were calculated. Adjusted results indicated that alendronate-treated patients were more likely to discontinue therapy as compared with etidronate-treated patients (1.404; 95% CI: 1.150, 1.714). After 1 year, 90.3% of patients were still taking etidronate compared with 77.6% for alendronate. No statistically significant differences were found between hormone replacement therapy and etidronate users (0.971; 95% CI: 0.862, 1.093) and hormone replacement therapy and alendronate users (0.824; 95% CI: 0.624, 1.088) after controlling for potential covariates. After 1 year, 80.1% of patients were still taking hormone replacement therapy, which decreased to 44.5% after 6 years. Increasing age and presence of incident non-vertebral fractures were found to be independent predictors of adherence. In conclusion, alendronate users were more likely to discontinue therapy than etidronate users over the follow-up period. Potential barriers to long-term patient adherence to osteoporosis therapies need to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Haynes RB, Taylor DW, Sackett DL (1979) Compliance in health care. John's Hopkins University Press, Baltimore

  2. Rosenstock IM (1975) Patients' compliance with health regimens. JAMA 234:402–403

    Article  CAS  PubMed  Google Scholar 

  3. Lutfey KE, Wishner WJ (1999) Beyond "compliance" is "adherence". Improving the prospect of diabetes care. Diabetes Care 22:635–639

    CAS  PubMed  Google Scholar 

  4. Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational placebo-controlled randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9:461–468

    Article  CAS  PubMed  Google Scholar 

  5. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344–1352

    CAS  PubMed  Google Scholar 

  6. Cano A (1994) Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20:91–99

    CAS  PubMed  Google Scholar 

  7. Ravnikar VA (1987) Compliance with hormone therapy. Am J Obstet Gynecol 156:1332–1334

    CAS  PubMed  Google Scholar 

  8. Castelo-Branco C, Figueras F, Sanjuan A et al. (1999) Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 6:307–311

    CAS  Google Scholar 

  9. Ettinger B, Pressman A, Silver P (1999) Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 6:282–289

    CAS  PubMed  Google Scholar 

  10. Ryan PJ, Harrison R, Blake GM et al. (1992) Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 99:325–328

    CAS  PubMed  Google Scholar 

  11. Doren M, Schneider HP (1996) The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 41:29–39

    CAS  PubMed  Google Scholar 

  12. Vestergaard P, Hermann AP, Gram J et al. (1997) Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 28:137–145

    Article  CAS  PubMed  Google Scholar 

  13. Cole RP, Palushock S, Haboubi A (1999) Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing. Women Health 29:101–115

    CAS  PubMed  Google Scholar 

  14. Sebaldt RJ, Adachi JD (1996) Canadian database of osteoporosis and osteopenia patients (CANDOO). Canadian organization for the advancement of computers in healthcare proceedings. 21:41–44

  15. Connelly MT, Richardson M, Platt R (2000) Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization. J Gen Int Med 15:542–550

    Article  CAS  Google Scholar 

  16. Kayser J, Ettinger B, Pressman A (2001) Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 8:328–332

    CAS  PubMed  Google Scholar 

  17. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321–333

    PubMed  Google Scholar 

  18. Hulley S, Furberg C, Barrett-Connor E et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288:58–66

    CAS  PubMed  Google Scholar 

  19. Karakoc B, Erenus M (1998) Compliance considerations with hormone replacement therapy. Menopause 5:102–106

    CAS  PubMed  Google Scholar 

  20. Watts NB, Harris ST, Genant HK et al. (1990) Intermittent cyclical etidronate treatment of post-menopausal osteoporosis. N Engl J Med 323:73–79

    CAS  PubMed  Google Scholar 

  21. Rossini M, Gatti D, Girardello S et al. (2000) Effects of two intermittent alendronate regimens in the prevention or treatment of post-menopausal osteoporosis. Bone 27:119–122

    Article  CAS  PubMed  Google Scholar 

  22. Cortet B, Bera-Louville A, Gauthier P et al. (2001) Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis: effect of adding hormone replacement therapy. Joint, Bone, Spine: Revue du Rhumatisme 68:410–415

    Google Scholar 

  23. Sahota O, Fowler I, Blackwell PJ et al. (2000) A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. Osteoporos Int 11:959–966

    Article  CAS  PubMed  Google Scholar 

  24. Porter AM (1969) Drug defaulting in a general practice. BMJ 1:218–222

    CAS  PubMed  Google Scholar 

  25. Ayd FJ Jr (1974) Single daily dose of antidepressants. JAMA 230:263–264

    Article  PubMed  Google Scholar 

  26. General Monograph Canadian Pharmacists Association (2001) In: Compendium of pharmaceuticals and specialties 36th edn. Canadian Pharmacists Association, Toronto, p 211

  27. Schumock G (1999) A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manage Q 18:50–58

    Google Scholar 

  28. Sarrel PM (1999) Improving adherence to hormone replacement therapy with effective patient-physician communication. Am J Obstet Gynecol 180:S337–340

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Greg Stephenson for his helpful comments with the manuscript and Catherine Krasnik for assisting with editorial requirements. This study was funded by a grant-in-aid from Procter & Gamble Pharmaceuticals Inc. Dr. A. Papaioannou is a recipient of a Career Scientist award from the Ontario Ministry of Health and Long Term Care.

Author information

Authors and Affiliations

  1. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    Alexandra Papaioannou, George Ioannidis, Jonathan D. Adachi, Mark Puglia & Pauline Boulos

  2. Department of Clinical Epidemiology and Biostatistics,St Joseph's Health Care, McMaster University, Hamilton, Ontario, Canada

    Rolf J. Sebaldt, Alan Tenenhouse, Annie Petrie & Charlie H. Goldsmith

  3. Clinical Health Sciences (Health Research Methodology Programme), McMaster University, Hamilton, Ontario, Canada

    Nicole Ferko

  4. Centre Hospitalier de l'Universite Laval, Ste-Foy, Quebec, Canada

    Jacques Brown

  5. Department of Medicine, University of Saskatchewan, Saskatoon, Saskatechewan, Canada

    Wojciech P. Olszynski

  6. Department of Medicine, University of Calgary, Calgary, Alberta, Canada

    David A. Hanley

  7. University of Toronto, Toronto, Ontario, Canada

    Robert Josse & Timothy M. Murray

  8. Geriatric Medicine , Hamilton Health Sciences, Chedoke Site, Wilcox Building, 2nd Floor, Sanatorium Road, Hamilton, Ontario, L8N 3Z5, Canada

    Alexandra Papaioannou

Authors
  1. Alexandra Papaioannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Ioannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan D. Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rolf J. Sebaldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicole Ferko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark Puglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacques Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alan Tenenhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wojciech P. Olszynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pauline Boulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David A. Hanley
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Robert Josse
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Timothy M. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Annie Petrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Charlie H. Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papaioannou, A., Ioannidis, G., Adachi, J.D. et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14, 808–813 (2003). https://doi.org/10.1007/s00198-003-1431-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1431-2

Keywords

Search

Navigation